These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

208 related articles for article (PubMed ID: 36882454)

  • 81. Risk of confirmed Guillain-Barre syndrome following receipt of monovalent inactivated influenza A (H1N1) and seasonal influenza vaccines in the Vaccine Safety Datalink Project, 2009-2010.
    Greene SK; Rett M; Weintraub ES; Li L; Yin R; Amato AA; Ho DT; Sheikh SI; Fireman BH; Daley MF; Belongia EA; Jacobsen SJ; Baxter R; Lieu TA; Kulldorff M; Vellozzi C; Lee GM
    Am J Epidemiol; 2012 Jun; 175(11):1100-9. PubMed ID: 22582210
    [TBL] [Abstract][Full Text] [Related]  

  • 82. Neurological autoimmune diseases following vaccinations against SARS-CoV-2: a case series.
    Kaulen LD; Doubrovinskaia S; Mooshage C; Jordan B; Purrucker J; Haubner C; Seliger C; Lorenz HM; Nagel S; Wildemann B; Bendszus M; Wick W; Schönenberger S
    Eur J Neurol; 2022 Feb; 29(2):555-563. PubMed ID: 34668274
    [TBL] [Abstract][Full Text] [Related]  

  • 83. Surveillance of Safety of 3 Doses of COVID-19 mRNA Vaccination Using Electronic Health Records.
    Niesen MJM; Pawlowski C; O'Horo JC; Challener DW; Silvert E; Donadio G; Lenehan PJ; Virk A; Swift MD; Speicher LL; Gordon JE; Geyer HL; Halamka JD; Venkatakrishnan AJ; Soundararajan V; Badley AD
    JAMA Netw Open; 2022 Apr; 5(4):e227038. PubMed ID: 35420661
    [TBL] [Abstract][Full Text] [Related]  

  • 84. COVID-19-associated Guillain-Barré syndrome: The early pandemic experience.
    Caress JB; Castoro RJ; Simmons Z; Scelsa SN; Lewis RA; Ahlawat A; Narayanaswami P
    Muscle Nerve; 2020 Oct; 62(4):485-491. PubMed ID: 32678460
    [TBL] [Abstract][Full Text] [Related]  

  • 85. Adverse events of special interest and mortality following vaccination with mRNA (BNT162b2) and inactivated (CoronaVac) SARS-CoV-2 vaccines in Hong Kong: A retrospective study.
    Wong CKH; Lau KTK; Xiong X; Au ICH; Lai FTT; Wan EYF; Chui CSL; Li X; Chan EWY; Gao L; Cheng FWT; Tang SCW; Wong ICK
    PLoS Med; 2022 Jun; 19(6):e1004018. PubMed ID: 35727759
    [TBL] [Abstract][Full Text] [Related]  

  • 86. SARS-CoV-2 Vaccination and Myocarditis in a Nordic Cohort Study of 23 Million Residents.
    Karlstad Ø; Hovi P; Husby A; Härkänen T; Selmer RM; Pihlström N; Hansen JV; Nohynek H; Gunnes N; Sundström A; Wohlfahrt J; Nieminen TA; Grünewald M; Gulseth HL; Hviid A; Ljung R
    JAMA Cardiol; 2022 Jun; 7(6):600-612. PubMed ID: 35442390
    [TBL] [Abstract][Full Text] [Related]  

  • 87. Guillain-Barre syndrome in Mexico: clinical features and validation of Brighton Collaboration Group criteria.
    López-Hernández JC; Galnares-Olalde JA; Gutiérrez A; Estrada SA; García-Grimshaw M; Vargas-Cañas ES
    Rev Neurol; 2022 Apr; 74(8):258-264. PubMed ID: 35383873
    [TBL] [Abstract][Full Text] [Related]  

  • 88. Dynamic IgG seropositivity after rollout of CoronaVac and BNT162b2 COVID-19 vaccines in Chile: a sentinel surveillance study.
    Sauré D; O'Ryan M; Torres JP; Zuniga M; Santelices E; Basso LJ
    Lancet Infect Dis; 2022 Jan; 22(1):56-63. PubMed ID: 34509185
    [TBL] [Abstract][Full Text] [Related]  

  • 89. A study of the association between seasonal influenza vaccines and the increased risk of Guillain-Barré syndrome using Vaccine Adverse Event Reporting System, 2018-2019.
    Fujimori M; Hasegawa S; Sasaoka S; Iguchi K; Nakamura M
    Pharmazie; 2021 Sep; 76(9):437-443. PubMed ID: 34481535
    [TBL] [Abstract][Full Text] [Related]  

  • 90. Guillain-Barré Syndrome and Variants Following COVID-19 Vaccination: Report of 13 Cases.
    Kim JE; Min YG; Shin JY; Kwon YN; Bae JS; Sung JJ; Hong YH
    Front Neurol; 2021; 12():820723. PubMed ID: 35153993
    [TBL] [Abstract][Full Text] [Related]  

  • 91. Guillain-Barré syndrome associated with SARS-CoV-2 infection: A systematic review and individual participant data meta-analysis.
    Hasan I; Saif-Ur-Rahman KM; Hayat S; Papri N; Jahan I; Azam R; Ara G; Islam Z
    J Peripher Nerv Syst; 2020 Dec; 25(4):335-343. PubMed ID: 33112450
    [TBL] [Abstract][Full Text] [Related]  

  • 92. Guillain-Barré syndrome presenting with facial diplegia following COVID-19 vaccination in two patients.
    Kanabar G; Wilkinson P
    BMJ Case Rep; 2021 Oct; 14(10):. PubMed ID: 34649856
    [TBL] [Abstract][Full Text] [Related]  

  • 93. Two possible etiologies of Guillain-Barré syndrome: mRNA-1273 (Moderna) vaccination and scrub typhus: A case report.
    Hwang BW; Bong JB
    Medicine (Baltimore); 2022 Dec; 101(48):e32140. PubMed ID: 36482517
    [TBL] [Abstract][Full Text] [Related]  

  • 94. Guillain-Barré syndrome after H1N1 vaccination in the United States: a report using the CDC/FDA Vaccine Adverse Event Reporting System (2009).
    Souayah N; Yacoub HA; Khan HM; Michas-Martin PA; Menkes DL; Maybodi L; Qureshi AI
    Neuroepidemiology; 2012; 38(4):227-32. PubMed ID: 22555646
    [TBL] [Abstract][Full Text] [Related]  

  • 95. Guillain-Barre syndrome, influenza, and influenza vaccination: the epidemiologic evidence.
    Vellozzi C; Iqbal S; Broder K
    Clin Infect Dis; 2014 Apr; 58(8):1149-55. PubMed ID: 24415636
    [TBL] [Abstract][Full Text] [Related]  

  • 96. Incidence, risk factors, natural history, and hypothesised mechanisms of myocarditis and pericarditis following covid-19 vaccination: living evidence syntheses and review.
    Pillay J; Gaudet L; Wingert A; Bialy L; Mackie AS; Paterson DI; Hartling L
    BMJ; 2022 Jul; 378():e069445. PubMed ID: 35830976
    [TBL] [Abstract][Full Text] [Related]  

  • 97. Chart-confirmed guillain-barre syndrome after 2009 H1N1 influenza vaccination among the Medicare population, 2009-2010.
    Polakowski LL; Sandhu SK; Martin DB; Ball R; Macurdy TE; Franks RL; Gibbs JM; Kropp GF; Avagyan A; Kelman JA; Worrall CM; Sun G; Kliman RE; Burwen DR
    Am J Epidemiol; 2013 Sep; 178(6):962-73. PubMed ID: 23652165
    [TBL] [Abstract][Full Text] [Related]  

  • 98. Risk of Guillain-Barré syndrome after exposure to pandemic influenza A(H1N1)pdm09 vaccination or infection: a Norwegian population-based cohort study.
    Ghaderi S; Gunnes N; Bakken IJ; Magnus P; Trogstad L; Håberg SE
    Eur J Epidemiol; 2016 Jan; 31(1):67-72. PubMed ID: 26008750
    [TBL] [Abstract][Full Text] [Related]  

  • 99. Near real-time surveillance for Guillain-Barré syndrome after influenza vaccination among the Medicare population, 2010/11 to 2013/14.
    Sandhu SK; Hua W; MaCurdy TE; Franks RL; Avagyan A; Kelman J; Worrall CM; Ball R; Nguyen M
    Vaccine; 2017 May; 35(22):2986-2992. PubMed ID: 28449973
    [TBL] [Abstract][Full Text] [Related]  

  • 100. Incidence of Guillain-Barré Syndrome post COVID-19: a systematic review of case reports and case series.
    Mahmoud H; Alhathla A; El-Fiky A; Alghamdi MS; Alwafi R; El-Sayed MS; Thabet AA; Alkhateeb AM; Elgendy SR; Hegazy R; Darweesh A
    Eur Rev Med Pharmacol Sci; 2023 Mar; 27(5):2152-2164. PubMed ID: 36930515
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.